Dermatology Doctors in Norman, OK Accepting Medicare

7 Dermatology doctors found. Showing 1 - 7

Dr. Paul Sylvester Atakpo, D.O. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3960 West Tecumseh Road, Suite 120, Norman, OK 73072 Phone: 405-217-3886    Fax: 405-217-3418

Dr. Sherrie G. Williamson, D.O. Dermatology Medicare: May Accept Medicare Assignments Practice Location: 3301 W Rock Creek Rd, Norman, OK 73072 Phone: 405-701-1010

David K Duncan, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2413 Palmer Cir, Norman, OK 73069 Phone: 405-321-3868

Dr. Joshua Stephen Weingartner, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3960 W. Tecumseh Road, Suite 120, Norman, OK 73072 Phone: 405-217-3886    Fax: 405-217-3419

Joel E Holloway, M.D. Dermatology Medicare: Medicare Enrolled Practice Location: 2500 Mcgee Dr Ste 148, Norman, OK 73072 Phone: 405-321-5022    Fax: 405-321-0785

Dr. Jessica N Doty, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3580 Rc Luttrell Dr Ste 102, Norman, OK 73072 Phone: 405-928-6100    Fax: 405-928-8222

Jennifer Carol Barnes Roberts, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2413 Palmer Cir, Norman, OK 73069 Phone: 405-310-3843    Fax: 405-321-5348

News Archive

Novel tiny spectrometer can detect food quality

Whether fruit, meat or cheese - the quality of food is not always as consumers would like it to be. But, in future, a spectrometer will allow them to gage the quality of food before they buy it. No bigger than a sugar cube, the device is inexpensive to manufacture and could one day even be installed in smartphones.

Studies examine risk factors for hospital readmission

In two studies published today in the Journal of Hospital Medicine, the risk factors for readmission to the hospital are examined based upon general medicine inpatients and those with at least two admissions in a six-month period. Alongside clinical factors such as having cancer, chronic diseases such as heart failure or lung disease, or being on high-risk medications, the studies identified other factors which increase the likelihood of a patient being readmitted which could help hospitalists focus in on these groups.

Biomoda submits new U.S. Patent application for CyPath lung cancer assay

Cancer diagnostics company Biomoda, Inc. filed an application for a new U.S. Patent that refines the use of fluorescent microscopy to increase the accuracy, sensitivity and specificity of the CyPath diagnostic assay for lung cancer.

First patient enrolled in phase III study of Bevacizumab and Trastuzumab in early breast cancer

A new international study for women with HER2-positive breast cancer is open for enrollment. The pivotal BETH (BEvacizumab and Trastuzumab Adjuvant Therapy in HER2-positive Breast Cancer) study is a Phase III clinical research trial that is investigating the benefits of combining two monoclonal antibodies, the anti-angiogenic, bevacizumab (Avastin) and the targeted therapy trastuzumab (Herceptin), together with chemotherapy for the treatment of patients with early stage HER2-positive breast cancer.

Patients unresponsive to anti-anemia drug have higher risk of cardiovascular disease, death

Patients with diabetes, kidney disease and anemia who don't respond to treatment with an anti-anemia drug have a higher risk of cardiovascular disease or death, researchers at UT Southwestern Medical Center have found.

Read more Medical News

› Verified 2 days ago